ALTAREX MEDICAL CORP.
|ALTAREX MEDICAL CORP. Patent applications|
|Patent application number||Title||Published|
|20090291075||BINDING AGENTS AND THEIR USE IN TARGETING TUMOR CELLS - The present invention concerns methods and compositions for administering a binding agent to a patient wherein the patient generates a response to autologous tumor. The binding agents target apoptotic tumor cells and facilitates the uptake of these apoptotic tumor cell are taken up by dendritic cells or other antigen presenting cells for processing and presentation to the immune system without the expression of circulating tumor-associated antigen (or without the need of circulating tumor antigen).||11-26-2009|
|20090220493||Reagents and methods for inducing an immune response to prostate specific antigen - The invention is an apparatus and method for the treatment of prostate cancer, and involves administering an antibody that specifically binds with prostate antigen.||09-03-2009|
|20090202560||Method for diagnosing efficacy of xenotypic antibody therapy - The invention concerns methods and compositions for intiating and/or enhancing an immune response by contacting a binding reagent with a soluble antigen, wherein the binding reagent-antigen pair generates an immune response to the antigen.||08-13-2009|
|20080311127||Combination therapy for treating disease - Disclosed are methods for treating cancer comprising administering a xenotypic antibody and a chemotherapeutic drug to a patient suffering from cancer. Also disclosed is a method for inducing a host immune response in a patient against a multi-epitopic in vivo tumor antigen present in the host serum, which antigen does not elicit an effective host immune response, comprising administering to the patient a chemotherapeutic drug and a composition comprising a binding agent that specifically binds to a first epitope on the antigen and allowing the binding agent to form a binding agent/antigen pair, wherein an effective host immune response is elicited against a second epitope on the antigen.||12-18-2008|
Patent applications by ALTAREX MEDICAL CORP.